Phase I Clinical Trial Data Review Complete - RECCE® 327 as an Intravenous Infusion Formulation
Highlights:
Independent examiners confirm Phase I R327 (I.V.) study in 80 human subjects
(eight cohorts), achieved all primary study end-points, met international regulatory
standards in data and showed R327 to be safe & well tolerated
Dosing was achieved commensurate with efficacy demonstrated in Gram-positive
& Gram-negative animal infection models to date
Phase I/II ‘fast infusion’ dosing of R327 IV is tracking to primary study end-points
with expected data read-outs in H2 2023
Phase I Clinical Trial Data Review Complete - RECCE® 327 as an...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.010(3.28%) |
Mkt cap ! $87.95M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.5¢ | 29.0¢ | $44.43K | 147.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 23668 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 7552 | 3 |
View Market Depth
| Last trade - 12.28pm 19/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |